

Renal hemodynamic effects of aliskiren in comparison to ramipril.

No registrations found.

Ethical review	Positive opinion
Status	Recruitment stopped
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON28302

Source

Nationaal Trial Register

Brief title

renal HEALTH-STudY

Health condition

essential hypertension, glomerular hypertension, overweight, obesity

Sponsors and support

Primary sponsor: University Medical Center Groningen (UMCG)

Source(s) of monetary or material Support: Unrestricted grant from Novartis

Intervention

Outcome measures

Primary outcome

1. Renal hemodynamics (GFR, ERPF, FF);
2. Blood pressure.

Secondary outcome

1. Volume status (extracellular fluid volume - ECFV);
2. RAAS parameters (plasma renin activity, plasma renin concentration, angiotensin II, aldosterone);
3. Urinary and serum kidney injury markers.

Study description

Background summary

N/A

Study objective

Aliskiren can decrease glomerular pressure, in respect to ramipril, in patients with essential hypertension and overweight/obesity, independent from blood pressure.

Study design

After a wash-out period of 6 weeks, patients are randomly assigned to either a 6-week treatment period with aliskiren or a 6-week treatment period with ramipril in a cross-over design. Between both treatment periods an 8-week wash-out period is present. Renal hemodynamics are measured at start and end of both 6-week treatment periods.

Intervention

1. Aliskiren 1dd 300 mg p.o.;
2. Ramipril 1dd 10 mg p.o..

Contacts

Public

Hanzeplein 1
G.D. Laverman
Groningen 9713 GZ
The Netherlands
+31 (0)50 3616161

Scientific

Hanzeplein 1

G.D. Laverman
Groningen 9713 GZ
The Netherlands
+31 (0)50 3616161

Eligibility criteria

Inclusion criteria

1. Male caucasian patients;
2. Age >18 and <70 years;
3. Overweight or obese (BMI >27 and <35 kg/m²);
4. Essential hypertension according to WHO-criteria (systolic and diastolic bloodpressure >140 or <90 mmHg, respectively);
5. Normal renal function (creatinine clearance >90 ml/min/1.73m²);
6. Normo- or microalbuminuria (albuminuria <300mg/day);
7. Written informed consent.

Exclusion criteria

1. Inability to meet inclusion criteria;
2. Previously treated (within 3 months prior to start of study) with aliskiren or ramipril;
3. Cardiovascular disease (myocardial infarction, angina pectoris, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, stroke, heart failure (NYHA I-IV), Diabetes Mellitus;
4. Active malignancy;
5. Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following:
 - A. History of active inflammatory bowel disease within the last six months;

- B. Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
 - C. Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last six months;
 - D. Pancreatic injury or pancreatitis within the last six months;
 - E. Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3x ULN at inclusion, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt;
 - F. Evidence of urinary obstruction or difficulty in voiding at inclusion.
6. History of severe hypersensitivity or contraindications to ramipril or aliskiren;
 7. Hypersensitivity to 125I-iothalamate or 131I-hippuran;
 8. History of angioedema;
 9. History of autonomic dysfunction (e.g. history of fainting or clinically significant orthostatic hypotension);
 10. Participation in any clinical investigation within 3 months prior to start of the study;
 11. Donation or loss of 400 ml or more of blood within 3 months prior to initial dosing;
 12. History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening;
 13. History of noncompliance to medical regimens or unwillingness to comply with the study protocol;
 14. Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.

Study design

Design

Study type:	Interventional
Intervention model:	Crossover

Allocation:	Non controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	01-01-2011
Enrollment:	16
Type:	Actual

Ethics review

Positive opinion	
Date:	22-09-2010
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

ID: 34045
Bron: ToetsingOnline
Titel:

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL2424
NTR-old	NTR2532
CCMO	NL33146.042.10
ISRCTN	ISRCTN wordt niet meer aangevraagd.
OMON	NL-OMON34045

Study results

Summary results

N/A